Remibrutinib Approval Marks First On-Label Dermographism Drug
Remibrutinib's FDA approval delivers the first on-label systemic therapy for symptomatic dermographism, ending decades of off-label antihistamine and omalizumab use for the skin-writing subtype of ch…